Lonza has formed a long-term, strategic collaboration with a global biopharma company for bioconjugation.
Lonza has announced, in a Dec. 2, 2020 press release, that it has formed a long-term, strategic collaboration with a global biopharma company for bioconjugation. The collaboration is expected to generate 200 new jobs in the Visp (Switzerland) biopark and operations will start at the end of 2022.
As per the terms of the agreement, Lonza will build two new customer-dedicated conjugation suites for the commercialization of antibody-drug conjugates (ADCs). The suites will total 1500 m2 of active manufacturing space and will form part of Lonza’s Ibex Dedicate model—a technology-agnostic supply solution.
“Bioconjugates represent an exciting class of molecules that are proving their worth and making a real difference to patients suffering from diseases such as cancer,” said Pierre-Alain Ruffieux, CEO, Lonza, in the press release. “From a manufacturing point of view, antibody-drug conjugates are challenging to produce, and we will be ensuring that our partner can de-risk supply and scale-up rapidly at this crucial moment of commercialization.”
“This collaboration demonstrates the power behind our Ibex Dedicate model, providing rapid and reliable delivery of complex therapeutics and tailored to individual customer needs,” added Jean-Christophe Hyvert, chief commercial officer, Lonza, in the press release. “Our Visp (CH) site now has all the elements required for antibody-drug conjugates at one site and this provides significant supply chain simplification and other logistical benefits to our customers, enabling them to reach patients faster.”
Source: Lonza
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.